Kevin Schuyler
About Kevin Schuyler
Kevin Schuyler, age 54, is a Class III director of Twin Vee PowerCats Co. (VEEE) serving since 2022 with his current term expiring at the 2027 annual meeting . He is the Board’s Lead Independent Director, chairs both the Audit and Compensation Committees, and serves on the Nominating & Corporate Governance Committee; he is designated the Audit Committee Financial Expert under Regulation S‑K . Schuyler is a CFA charterholder; he graduated with honors from Harvard College and holds an MBA from the University of Virginia Darden School . Professionally, he is Managing Director at CornerStone Partners (~$26B under management), and previously served as CIO at The Nature Conservancy; earlier roles include the Chicago Board of Trade (Louis Dreyfus Corporation) and McKinsey & Company .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| CornerStone Partners (Charlottesville, VA) | Managing Director | Since 2006 | Full-service institutional CIO office; approx. $26B AUM |
| The Nature Conservancy | Chief Investment Officer | Prior to 2006 | Led investment function for the world’s largest conservation nonprofit |
| Chicago Board of Trade / Louis Dreyfus Corporation | Early career – trading/markets | Not disclosed | Markets experience foundation |
| McKinsey & Company | Management Consultant | Not disclosed | Strategy/operations advisory experience |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) | Chairman of the Board and Lead Independent Director | Chairman since Aug 2022; Director since Apr 2016 | Board leadership in a public biopharma company |
| Wildrock, Inc. (non-profit) | Director | Not disclosed | Local not-for-profit board member |
Board Governance
- Independence: The Board determined Schuyler is “independent” under Nasdaq and SEC Rules 10A‑3 and 10C‑1 .
- Leadership: CEO serves as Board Chair; Schuyler is Lead Independent Director, providing counterbalance to combined CEO/Chair structure .
- Committee assignments:
- Audit Committee: Chair; all members independent; charter on website; Schuyler is Audit Committee Financial Expert .
- Compensation Committee: Chair; all members independent .
- Nominating & Corporate Governance Committee: Member .
| Body | 2024 Meetings Held | Attendance Disclosure |
|---|---|---|
| Board of Directors | 7 | Each current director attended ≥75% of aggregate Board and committee meetings during their service period in 2024 |
| Audit Committee | 4 | ≥75% for each current director |
| Compensation Committee | 4 | ≥75% for each current director |
| Nominating & Corporate Governance Committee | 1 | ≥75% for each current director |
Policies enhancing oversight:
- Related-Party Transaction Policy overseen by Audit Committee, with detailed approval/ratification procedures and independence considerations for directors .
- Anti-hedging/anti-pledging policy prohibits directors from hedging or pledging company stock .
Fixed Compensation
- Structure change: Following the November 26, 2024 Forza merger, the Board moved from meeting/committee fees to annual retainers; Schuyler’s annual retainer set at $100,000 for his roles (Lead Independent Director, Audit Chair, Compensation Chair, Nominating member) .
- 2024 cash actually earned: $84,500, paid quarterly in arrears and prorated for partial quarters as applicable .
| Item | Amount | Period | Notes |
|---|---|---|---|
| Annual cash retainer (Lead Independent Director + Chairs) | $100,000 per year | Effective as of Nov 26, 2024 | Retainer reflects consolidated role responsibilities |
| Fees earned (cash) | $84,500 | FY 2024 | Paid quarterly in arrears; prorated if partial service during quarter |
Historic context (pre-merger): Prior to November 26, 2024, non-employee director compensation included base annual fee and separate committee/member/chair fees ($5,000 base; Audit $4,000 member/$12,000 chair; Compensation $4,000 member/$10,000 chair; Nominating $3,000 member/$5,000 chair) .
Performance Compensation
- Equity grants: Non-employee directors serving in 2023 received options for 5,500 shares under the 2021 Plan; these vested upon issue on August 16, 2024 .
- Forza option conversion: On November 26, 2024, Schuyler’s previously issued Forza options (5,500 shares, granted Aug 11, 2022) converted into options for 3,364 Twin Vee shares and vested upon issue .
- Option awards recognized in 2024: $1,551 (grant-date fair value per the Director Compensation Table) .
- Outstanding options (aggregate) as of Dec 31, 2024: 14,364 .
| Award | Grant Date | Shares/Options | Vesting | Status |
|---|---|---|---|---|
| 2021 Plan – Non-employee director options | 2023 service year; vested Aug 16, 2024 | 5,500 | Vested upon issue on Aug 16, 2024 | Vested |
| Forza 2022 Plan – converted to Twin Vee options | Originally Aug 11, 2022; converted Nov 26, 2024 | 3,364 (post-conversion) | Vested upon issue on Nov 26, 2024 | Vested |
| Option awards recognized (value) | 2024 | $1,551 | N/A | Reported in Director Compensation Table |
| Outstanding option awards (aggregate) | As of Dec 31, 2024 | 14,364 | N/A | Outstanding balance |
Note: Strike prices/expirations for director-specific grants are not disclosed in the director section; no PSU/RSU or performance metric-based director equity was disclosed .
Other Directorships & Interlocks
| Company | Exchange/Ticker | Role | Committees/Notes |
|---|---|---|---|
| Adial Pharmaceuticals, Inc. | NASDAQ: ADIL | Chairman; Lead Independent Director | Public company board leadership since Aug 2022; director since Apr 2016 |
- Interlocks/conflicts: No related-party transactions involving Schuyler were disclosed in the Company’s related-party section (which lists leases and services tied to other executives) .
Expertise & Qualifications
- Lead Independent Director with dual chair roles (Audit and Compensation), providing governance leverage in oversight of financial reporting and pay practices .
- Audit Committee Financial Expert designation under Regulation S‑K Section 407 .
- CFA charterholder; Harvard College (honors); MBA, UVA Darden .
- Deep investment office leadership (CornerStone Partners; prior CIO at The Nature Conservancy) .
Equity Ownership
Beneficial ownership as of October 15, 2025 (record date: 2,237,299 shares outstanding) :
| Item | Amount | Percent of Outstanding | Notes |
|---|---|---|---|
| Shares owned (common) | 6,253 | <1% | Sole voting/investment power unless otherwise indicated |
| Options beneficially owned | 4,436 | — | 3,435 options will vest/be exercisable within 60 days of Oct 15, 2025 |
| Total beneficial ownership | 9,688 | <1% | Includes options exercisable within 60 days per SEC rules |
| Shares pledged as collateral | None disclosed; pledging prohibited by policy | N/A | Anti-hedging/anti-pledging policy applies to directors |
| Ownership guidelines | Not disclosed | N/A | No director stock ownership guideline disclosure found |
Governance Assessment
Positive signals:
- Strong independence and governance roles: Schuyler is independent, Lead Independent Director, and chairs Audit and Compensation, enhancing board oversight in financial reporting and pay .
- Audit expertise: Formal designation as Audit Committee Financial Expert supports robust financial controls and reporting quality .
- Attendance/engagement: The Board and committees met regularly in 2024 (Board 7; Audit 4; Compensation 4; Nominating 1), and each current director met ≥75% attendance thresholds, indicating consistent participation .
- Policies: Anti-hedging/anti-pledging policy and related-party transaction review framework help align interests and mitigate conflicts; Audit Committee reviews related-party dealings .
Watch items / potential red flags:
- Low personal share ownership: Schuyler beneficially owns <1% of shares outstanding (9,688 total including near-term exercisable options), which may limit economic alignment versus larger holders .
- Compensation mix shift: Move to a higher fixed cash retainer ($100,000) for director roles post-merger increases guaranteed pay versus prior per-meeting/committee fees; equity awards for directors were minimal in 2024, potentially dampening at-risk alignment .
- Board structure: CEO serves as Board Chair; while mitigated by a Lead Independent Director, combined roles can concentrate authority and warrant continued monitoring of independent oversight .
- Reincorporation proposal: Board’s proposal to convert from Delaware to Nevada increases statutory protections for directors/officers and may reduce certain stockholder rights (e.g., higher removal thresholds, broader exculpation), a governance environment change that investors should evaluate; while not director-specific, Schuyler’s leadership role implies influence on governance posture .
Overall, Schuyler’s audit and compensation leadership, independence, and financial expertise are positives for board effectiveness; his relatively small ownership and the Company’s governance shift considerations (Nevada reincorporation; CEO/Chair combination) are the key governance angles to monitor .